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The rules that govern complementation of mutant and wild-type mitochondrial genomes in human cells were
investigated under different experimental conditions. Among mitochondrial transformants derived from an
individual affected by the MERRF (myoclonus epilepsy associated with ragged red fibers) encephalomyopathy
and carrying in heteroplasmic form the mitochondrial tRNALYS mutation associated with that syndrome,
normal protein synthesis and respiration was observed when the wild-type mitochondrial DNA exceeded 10%
of the total complement. In these transformants, the protective effect of wild-type mitochondrial DNA was
shown to involve interactions of the mutant and wild-type gene products. Very different results were obtained
in experiments in which two mitochondrial DNAs carrying nonallelic disease-causing mutations were
sequentially introduced within distinct organelles into the same human mitochondrial DNA-less (p°) cell. In
transformants exhibiting different ratios of the two genomes, no evidence of cooperation between their products
was observed, even 3 months after the introduction of the second mutation. These results pointed to the
phenotypic independence of the two genomes. A similar conclusion was reached in experiments in which
mitochondria carrying a chloramphenicol resistance-inducing mitochondrial DNA mutation were introduced
into chloramphenicol-sensitive cells. A plausible interpretation of the different results obtained in the latter
two sets of experiments, compared with the complementation behavior observed in the heteroplasmic MERRF
transformants, is that in the latter, the mutant and wild-type genomes coexisted in the same organelles from
the time of the mutation. This would imply that the way in which mitochondrial DNA is sorted among different
organelles plays a fundamental role in determining the oxidative-phosphorylation phenotype in mammalian
cells. These results have significant implications for mitochondrial genetics and for studies on the transmission
and therapy of mitochondrial DNA-linked diseases.
Despite the large number of studies on the expression of
artificially produced mitochondrial DNA (mtDNA) mutations
and the phenotype of somatic cell hybrids and cybrids, infor-
mation on mitochondrial genome interactions in mammalian
cells is still very limited. The dependence of such interactions
on the distribution of the mtDNA molecules among the
mitochondria, which changes continuously throughout division
and, possibly, fusion of the organelles, and the difficulty of
investigating mtDNA sorting in a cell account in part for the
present lack of understanding of how much the mitochondrial
genomes interact in mammalian cells. The recent discovery of
a variety of mtDNA mutations associated with diseases in
humans (47) and the growing evidence of accumulation of
mtDNA mutations with aging in somatic tissues (12-14, 19, 43)
have raised a number of questions about the occurrence and
frequency of intermixing of mutant and wild-type mtDNA
and/or their products within a cell and the role that comple-
mentation or competition phenomena between these products
play in determining the cell phenotype. While it is clear that
the respiratory competence of a cell containing both mutant
and wild-type mtDNA (heteroplasmic) depends on the pro-
portion of the two types ofmtDNA and on the capacity of their
products to cooperate or compete with each other, only
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fragmentary data on the mechanisms which would permit such
cooperation or competition to occur are available.
Evidence derived from the analysis of heteroplasmic cybrids
produced by transfer of mitochondria from patients affected by
the MELAS (mitochondrial myopathy, encephalopathy, lactic
acidosis, and stroke-like episodes) encephalomyopathy, caused
by a mitochondrial tRNALeU(UUR) mutation, into mtDNA-less
(p°) cells (8) and from the investigation of myotubes that are
heteroplasmic for the MERRF (myoclonus epilepsy associated
with ragged red fibers) mitochondrial tRNALYS mutation (5)
has clearly indicated that a small minority of wild-type mtDNA
can protect the cell against the phenotypic effects of the
mtDNA mutation. However, such experiments did not clarify
whether this protective effect reflects the capacity of the
wild-type mtDNA minority to provide enough respiratory
capacity for the cellular needs even when completely segre-
gated from the mutant mtDNA or, alternatively, whether
intermixing and cooperation of the wild-type and mutant gene
products, presumably through mitochondrial fusion, are re-
quired for the protective effect to occur.
Evidence suggesting cooperation between the products of
wild-type and deleted mtDNA in cybrids derived from cells of
a patient affected by chronic external ophthalmoplegia has
been provided by the observation of translation products
corresponding in size to the expected fusion proteins encoded
in the deleted mtDNA (20). In fact, because of the removal of
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essential tRNA genes by the deletion, the synthesis of such
fusion products would require the participation of tRNAs
transcribed from the wild-type genomes. Similarly, competition
for tRNAs encoded in wild-type mtDNA by mRNAs tran-
scribed from wild-type and mutant mtDNAs, again pointing to
intermixing of mitochondrial gene products, has been sug-
gested to occur in segments of skeletal muscle fibers of patients
affected by a mitochondrial disease (Kearns-Sayre syndrome)
characterized by accumulation of large-scale deletions in
mtDNA (41). However, in both of the above-mentioned cases,
the results could not distinguish between the possibility that
the presence of normal and deleted mtDNAs in the same
mitochondrion resulted from fusion of two homoplasmic mi-
tochondria, one containing only deleted mtDNA and the other
containing only wild-type mtDNA, and the preexistence of
both mtDNAs in the same mitochondrion from the time of the
mutation event. Evidence which had been interpreted to
suggest an intermixing and cooperation of gene products of
mutant and wild-type mtDNAs originally carried in distinct
organelles had been reported in an earlier study involving
hybrids or cybrids between chloramphenicol (CAP)-sensitive
(CAPS) human cells and CAP-resistant (CAPr) cells or cyto-
plasts derived therefrom, respectively (35).
In this study, the availability of donor cells derived from
patients affected by either of two mitochondrial diseases
caused by mutations in distinct mitochondrial tRNA genes has
allowed us to introduce independently the two mtDNAs into
the same p0 cell and thus to test the occurrence of comple-
mentation between mitochondrial genomes carried by origi-
nally distinct organelles in the absence of a significant back-
ground due to lack of complementation. No evidence of
cooperation was observed between the products of the two
genomes, pointing to the phenotypic independence of these
genomes. Similarly, no interactions between mutant and wild-
type mtDNAs were detected in experiments in which mito-
chondria carrying CAP' mtDNA were introduced by cytoplast
fusion into CAPS cells. In contrast to the above situations, in
heteroplasmic MERRF transformants, derived from donor
cells in which the mutant and wild-type genomes coexisted
from the mutation event, extensive interactions between mu-
tant and wild-type gene products were observed, pointing to a
probable intramitochondrial event.
MATERIALS AND METHODS
Cell lines and media. The bromodeoxyuridine (BrdU)-
resistant 143B.TK- cell line (ATCC CRL 8303; hereafter
referred to as 143B) was grown in Dulbecco's modified Eagle's
medium (DMEM) containing 4.5 mg of glucose per ml and
supplemented with 5% fetal calf serum (FBS) and 100 ,ug of
BrdU per ml. The p0206 cell line, an mtDNA-less derivative of
143B.TK- obtained by long-term exposure of the cells to low
concentrations of ethidium bromide (25), was grown in
DMEM supplemented with 5% FBS plus 100 ,ug of BrdU and
50 ,ug of uridine per ml. Transformant pT72, derived from a
myoblast culture from an MERRF patient by mitochondrion
transfer into the p0701.2a cell line (obtained by ethidium
bromide treatment of the simian virus 40-transformed human
fibroblast strain GM701 [26a]) (9), was grown in DMEM
supplemented with 10% FBS. The other transformants used in
the present work were grown in DMEM supplemented with
5% (MERRF transformants) or 10% (MELAS and double-
genome transformants) dialyzed FBS and 100 jig of BrdU per
ml except for transformants 59A x pT72-22, 59A x pT72-34,
2SD x pT72-25, and 2SD x pT72-45. These transformants grew
extremely slowly in the above medium for the first 2 weeks
postfusion but started growing at reasonable rates (with dou-
bling times of between 22 and 28 h) after the medium was
supplemented with 50 jig of uridine per ml; this uridine
requirement presumably reflected the nearly complete absence
of mitochondrial protein synthesis and respiration in these
transformants. The CAP23 cell line, a CAPr derivative of the
VA2B cell line, previously isolated and characterized in this
laboratory (31, 32) and shown to exhibit a T-to-C transition at
position 2991, one of three known sites of CAPY mutations in
the 16S rRNA gene of mammalian cells (26), was grown in
DMEM with 10% calf serum, 3 jig of 8-azaguanine per ml, and
40 jig of CAP per ml.
Myoblast culture and mitochondrion-mediated p0206 cell
transformation. A mass myoblast culture was established from
a muscle biopsy specimen from a patient with MERRF by a
previously reported procedure (29) and used for p0206 cell
transformation by cytoplast fusion, carried out as described
previously (25). In particular, enucleated myoblasts were fused
to -5 x 105 to 1 x 106 p0206 cells, and transformants were
isolated and maintained in DMEM supplemented with 10%
dialyzed FBS and 100 jig of BrdU per ml. The population
doubling time (DT) of the transformants was determined by
using the formula DT = (t - tj)log 2/(logN - log NO), where
N is the cell number and t is the time when the cells were
counted.
Subcloning of MERRF transformants. One or more sam-
ples, each containing approximately 20 p0 cell transformants
derived from myoblasts from the MERRF patient, were mixed
with 105 p0206 cells in DMEM with 5% FBS and 100 jig of
BrdU per ml and plated into 96-well plates at a final cell
density of 0.2 transformant and 103 p0 cells per well. Colonies
were recognized between 1 and 2 weeks after plating and
transferred by trypsinization into the wells of a 24-well plate or
into 3.5-cm plates. In some experiments, as specified below,
subcloning was carried out in the absence of p0206 feeder cells.
Fusion of MERRF transformant cytoplasts with MELAS
transformants. A large excess (-5 x 105 to 1 x 106) of cells
of the MERRF transformant pT72 were enucleated by centrif-
ugation in the presence of cytochalasin B and then fused with
a small number of cells (-6,000) of the MELAS transformant
59A or 2SD (8). The transformants were isolated in DMEM
supplemented with 10% dialyzed FBS and 100 jig of BrdU per
ml. In this medium, only unfused MELAS transformants and
cybrids between these transformants and pT72 cytoplasts were
expected to survive; residual nonenucleated pT72 cells or
hybrids between these and the MELAS transformants were
expected to be killed by BrdU phosphorylated by the thymi-
dine kinase encoded in the pT72 nucleus. To identify the
cybrids, the clones were screened for the presence of the
MERRF mutation by PCR amplification of an mtDNA frag-
ment encompassing the mutation, using a mismatched primer
and NaeI restriction digestion, as described below. Six clones
exhibiting the MERRF mutation were identified after screen-
ing 116 clones.
Fusion of CAP23 cytoplasts with 143B cells. In these exper-
iments, a small number of CAP23 cells (-2,000 cells) were
enucleated by centrifugation in the presence of cytochalasin B
and then fused with a large excess of 143B cells (- 106 cells). In
a first fusion experiment, 13 cybrids were isolated and main-
tained in DMEM with 10% dialyzed FBS in the presence of
100 jig of CAP and 100 jig of BrdU per ml until the time of
analysis (57 to 58 days after fusion). In a second experiment, 4
cybrids were maintained in 100 jig of CAP per ml until the
time of analysis (36 days after fusion), and 12 cybrids were
transferred, 31 days after fusion, to a medium containing 100jig of BrdU per ml and either 25 jig of CAP per ml (9 cybrids)
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or 25 pLg of CAP plus 50 pLg of uridine per ml (3 cybrids) and
kept in these media for 5 days before analysis.
DNA analysis. Total DNA samples were prepared from
unlabeled cultured cells with an Applied Biosystems 340A
DNA extractor or by direct lysis in PCR buffer (10 mM
Tris-HCl [pH 8.4], 50 mM KCl, 1 mM MgCl2) containing 100
pug of proteinase K per ml and 0.5% Tween 20 (24). Total
DNA from biopsy specimens was extracted as described pre-
viously (37). For the detection of the MERRF A-*G transition
in the mitochondrial tRNALYS gene (40, 53) at position 8344 in
the Cambridge human mtDNA sequence, an mtDNA segment
which encompasses the mutation was amplified by PCR, using
a mismatched primer which generated a new NaeI site over the
mutated template, and then digested with NaeI (52). In
particular, samples of total cell DNA from the original muscle
biopsy specimen, the mass myoblast culture, the mitochondrial
transformants, or 143B cells were processed in a thermal cycler
(Eppendorf or Perkin-Elmer Cetus), using Taq polymerase
(Promega) and oligonucleotides corresponding to the L-strand
between positions 8191 and 8210 and to the H-strand between
positions 8345 and 8364 (5'-TCACTGTAAAGAGGTGC
CGG; underlined nucleotides differ from the Cambridge se-
quence and create an NaeI site when the MERRF mutation is
present) as primers. The amplified fragments were digested
with NaeI in the presence of the 654-bp EcoRI-SalI fragment
of pBR322 DNA as an internal marker for completion of
digestion and analyzed by electrophoresis through a 5% poly-
acrylamide-7 M urea gel for the detection and quantitation of
the MERRF mutation. In some experiments, as specified
below, the amplified fragments were digested with NaeI in the
presence of the 1,075-bp XmnI-KpnI fragment of pBluescript
KS+ DNA as an internal digestion marker; equal amounts of
the various mixtures were then analyzed by electrophoresis
through a 5% polyacrylamide gel.
In order to quantitate the proportion of mtDNA molecules
carrying the MERRF mutation in a DNA sample by specific
restriction enzyme digestion of the mtDNA PCR products, a
mixed-template standard curve was constructed (40). For this
purpose, the PCR-amplified products of the mtDNAs from the
previously isolated pTl transformant, containing in homoplas-
mic form the MERRF mutation, and pT5 transformant, con-
taining in homoplasmic form the corresponding wild-type
sequence (9), were cloned in the BamHI and EcoRI sites of the
pBluescript KS+ vector (Stratagene), and mixtures in different
ratios of the whole plasmids pKS+.pTl-1 and pKS+.pT5-2,
containing the mutant and the wild-type sequence, respec-
tively, were subjected to PCR amplification and NaeI digestion
in the presence of the EcoRI-SalI fragment of pBR322 DNA
mentioned above as an internal marker for completion of
digestion. The products were run on a 5% polyacrylamide-7 M
urea gel, and the proportion of digested and undigested
molecules was determined by using an LKB laser densitometer
after ethidium bromide staining. Figure la compares the
mixed-template standard curve (T) thus constructed for the
MERRF mutation with the mixed-product standard curve (P)
constructed by mixing, in different ratios, the PCR products
independently amplified from pKS+.pTl-1 and pKS+.pT5-2
and then subjecting the mixtures to restriction enzyme diges-
tion. As shown previously (40), the T curve differs significantly
from the P curve. This difference presumably results from the
formation, during the final stages of PCR amplification, of
heteroduplexes of wild-type and mutant mtDNA which are
totally or partially resistant to the restriction enzyme digestion.
For the detection of the MELAS A-+G transition at position
3243 in the tRNALeU(UUR) gene (17, 27, 45), advantage was
taken of the fact that the mutation creates an ApaI restriction
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FIG. 1. (a) Standard curves for quantitation of the MERRF muta-
tion in mtDNA. (b) Standard curves for quantitation of the CAP'
mutation in mtDNA. T, mixed-template standard curve; P, mixed-
product standard curve; WT, wild type.
site and therefore it is possible to use ApaI digestion to
monitor the presence and proportion of mutated mtDNA. For
quantitation of the MELAS mutation, a mixed-template stan-
dard curve, constructed as described previously (51), was used.
For the detection of the CAPr T-to-C transition at position
2991 in the 16S rRNA gene of CAP23 mtDNA, an mtDNA
fragment which encompasses the mutation was amplified by
PCR with oligonucleotides corresponding to the L-strand
between positions 2819 and 2838 and to the H-strand between
positions 2992 and 3016 (5-CACCATCGGGATGTCCTGA
TCCaAC-3'; the underlined nucleotide differs from the Cam-
bridge sequence and creates an AatII site when the CAPr
mutation is present) as primers. The amplified fragments from
the cybrids between CAP23 cytoplasts and 143B cells or from
143B, VA2B, or CAP23 cells were digested with AatII in the
presence of the 775-bp fragment (including an 8-nucleotide tail
of one of the primers) of human mtDNA between positions
7626 and 8392, amplified by PCR from 143B total cell DNA, as
an internal marker for completion of digestion. A portion of
each digested mixture was then run through a 5% polyacryl-
amide gel for the detection and densitometric quantitation of
the CAPr mutation.
To correct the data for the formation of heteroduplexes of
wild-type and mutant mtDNA which may be partially or totally
resistant to AatII digestion during PCR amplification, a tem-
plate standard curve was constructed. For this purpose, an
mtDNA fragment from CAP23 cells harboring the CAP'
mutation and the corresponding mtDNA fragment from the
VA2B cell line, the parent of CAP23, were amplified by PCR,
and then mixtures in different ratios of the two PCR products
were digested with AatII in the presence of the internal
digestion marker and analyzed as specified above. Figure lb
compares the mixed-template standard curve (T) thus con-
structed for the CAPr mutation with the mixed-product stan-
dard curve (P) constructed by mixing, in different ratios, the
PCR products independently amplified from CAP23 mtDNA
and VA2B mtDNA and then subjecting the mixtures to AatII
digestion. Here too, one observes a significant difference
between the T and P curves, which presumably reflects the
presence of heteroduplexes.
Southern blot analysis of equal samples of total cell DNA
digested with BamHI for quantitation of mtDNA was carried
out with the entire HeLa cell mtDNA, 32p labeled by random
priming (15), as a probe. To correct for possible quantitative
variations among different DNA samples, the same membrane
was probed with a nuclear 28S rRNA gene fragment, con-
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FIG. 2. Transformants obtained by mitochondrion transfer from MERRF proband myoblasts into human p0 cells exhibit variable genotype and
phenotype. (a) Genotype of the proband muscle (Mu) biopsy specimen, the myoblast (Myo) culture, five mitochondrial transformants, and 143B
cells, analyzed by PCR amplification of total DNA with a mismatched primer and by running the PCR products on a 5% polyacrylamide-7 M urea
gel, as described in Materials and Methods. Indicated are the sizes of the uncut PCR product in the muscle, myoblast, and transformant DNA
samples (165 bp) and that of the larger fragment (147 bp) produced by NaeI cleavage of the mutation-containing PCR product. The size of the
PCR product in the proband-derived DNA samples is 9 bp smaller than that obtained in the 143B DNA sample (174 bp) because of a
nonanucleotide deletion frequently present in Asian populations (22). Lane M, HaeIII-digested pBluescript KS+ DNA; lane pBR322/NaeI,
fragments produced by NaeI cleavage of the EcoRI-SalI fragment of pBR322; lane pBR322, EcoRI-SalI fragment of pBR322; %MT, percentage
of mutant mtDNA. (b) Patterns of mitochondrial translation products (2-h [35S]methionine labeling, 25 jig of protein run on gel). COI, COII, and
COIII, subunits I, II, and III of cytochrome c oxidase, respectively; ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, subunits 1, 2, 3, 4, 4L, 5, and
6 of the respiratory chain NADH dehydrogenase, respectively; A6 and A8, subunits 6 and 8 of the H+-ATPase, respectively; CYTb, apocytochrome
b. The asterisks indicate abnormal translation products. (c) Rate Of 02 consumption in the five transformants and, for comparison, in 143B cells.
The times after mitochondrial transfer that the mtDNA analysis was performed were 72 days (KT1), 60 days (KT5), 60 days (KT7), 27 days (KT10),
and 17 days (KT11).
structed by PCR amplification with oligonucleotides corre-
sponding to positions 1503 to 1522 and 1981 to 2000 in the 28S
rRNA gene (16), purified on an agarose gel, and 32P labeled by
random priming. Radioactivity was quantitated by laser densi-
tometry of the autoradiograms.
Mitochondrial protein synthesis and 02 consumption anal-
ysis. Cultures of individual transformants or 143B cells (-2 x
105 cells) were labeled with [35S]methionine (>800 Ci/mmol,
25 pCi/ml) for 2 h in the presence of 100 pg of emetine per ml,
and the samples were then washed, trypsinized, lysed with 1%
sodium dodecyl sulfate (SDS), and run on SDS-exponential
polyacrylamide gradient gels, as described previously (9). 02
consumption measurements were made as detailed earlier
(25).
RESULTS
Isolation of heteroplasmic mitochondrial transformants
carrying the MERRF tRNALYS mutation. The proband from
which the myoblast cultures were derived was from a 25-year-
old Japanese male with characteristic symptoms of MERRF
syndrome, including myoclonic epilepsy, ataxia, dementia, and
mitochondrial myopathy with ragged red fibers. His mother
exhibited similar but milder symptoms. Analysis of DNA from
muscle biopsy specimens showed the presence of the mito-
chondrial tRNALYS mutation in both the patient and the
mother (52). A mass myoblast culture was established from a
muscle specimen of the proband, and myoblast-derived cyto-
plasts were fused to a large excess of p0206 cells. Eleven
presumptive mitochondrial transformants were isolated by
growing the cell fusion mixtures in medium containing BrdU
and lacking uridine (25). As shown in Fig. 2a, the muscle
specimen and the mass myoblast culture exhibited the
tRNALYS mutation in --91% of the mtDNA molecules. Nine of
the 11 transformants were found to contain more than 90%
mutant mtDNA, while the other 2 (KT5 and KT7) contained
between 80 and 90% mutant mtDNA. These two transfor-
mants and three of the others (KT1, KT10, and KT11) were
chosen for further study and maintained in continuous culture
over an 8- to 9-month period. During this time, in KT1, KT10,
and KT11, the wild-type mtDNA level remained constant at 5
to 8%, whereas in KT5 and KT7, the wild-type mtDNA level
declined fairly rapidly from 15 and 17%, respectively, 1 to 2
months after isolation, to -9%, and slowly reached a level of
6 to 7% after 7 months.
Figure 2b displays the mitochondrial translation products of
the transformants labeled with [35S]methionine for 2 h in the
presence of 100 ,ug of emetine per ml 16 to 17 weeks after
b
143B KTI KT5 KT7 KTIO KTIll
c
6F
143B
-o
= 4
E --.
o c
0n --
c E
O -
O 9+20
KT 7
KTS
F7
KTI KT1O KTI
HH
MOL. CELL. BIOL.
COMPLEMENTATION BEHAVIOR OF mtDNA IN HUMAN CELLS
ND5--
CO I - -
ND4/-
CYTb,-
ND2--
ND 1f
comI\
COll-
A6/
KTI
143B 1 2 3 4 5
Sf*
KT5
1438 1 2 3 4 5
ND66--
ND3/
ND4L- -
ABr
% MT 0 88 92 91 91 88
02 5.0 0.68 0.64 n.d. 0.56 1.0
90 92 84 86 93 92 89
2.0 1.3 2.8 2.4 1.2 1.1 2.4
KT7
6 7 14381 2 3 4 5I~~
FIG. 3. Genotype and phenotype of subclones of individual MERRF transformants. The KTI, KT5, and KT7 transformants were subcloned,
respectively, 8 weeks, 8 and 14 weeks, and 14 weeks after mitochondrion transfer, and five subclones of KTI and KT7 and seven subclones of KT5
(1 to 5 from the second subcloning experiment and 6 and 7 from the first subcloning experiment) were analyzed for genotype, 02 consumption,
and mitochondrial protein synthesis (2-h labeling, 25 ,ug of protein run on gel). Except for the subclones of KT1 and subclones 6 and 7 of KT5,
all subclones were isolated in the presence of p0206 feeder cells. Below the fluorograms are indicated the percent mutant (MT) mtDNA content
and the 02 consumption (in femtomoles per minute per cell) of the individual cell lines. n.d., not determined. See the legend to Fig. 2b for other
details.
fusion. Considerable variability in the labeling of the mtDNA-
encoded proteins was observed among the transformants.
Transformants KT1, KT10, and KT11 showed various de-
creases in protein labeling relative to the 143B parental cells,
as well as the presence of an abnormal translation product
migrating faster than ND4 (asterisks in Fig. 2b) previously
identified as characteristic of MERRF patient myoblasts (5, 9)
and p0 transformants derived therefrom (9). By contrast, the
level of labeling and the pattern of the mitochondrial transla-
tion products of KT5 and KT7, which at the time of analysis
had a mutant mtDNA content of 91 and 87%, respectively,
appeared to be fairly similar to those of 143B cells, with a small
amount of the abnormal band. Correspondingly, the rate of 02
consumption, analyzed 15 to 17 weeks after fusion, was
strongly decreased in KTi, KT10, and KT11 (<0.7 fmol/min/
cell), moderately decreased in KT5 (2.5 fmol/min/cell), and
only slightly reduced in KT7 (3.8 fmol/min/cell) compared with
the rate in 143B cells (Fig. 2c).
Subcloning of MERRF transformants. In order to investi-
gate the intercellular heterogeneity in genotype and phenotype
of the transformants, five to seven subclones were isolated, as
described in Materials and Methods, from each of the KT1,
KT5, and KT7 clones, at times corresponding, respectively, to
8, 8 and 14, and 14 weeks after their isolation. As shown in Fig.
3, the individual subclones from each transformant exhibited
relatively little variation in the proportion of wild-type
mtDNA, with its average approaching that of the parental
clone (10 versus 7% in KT1, 9 versus 12% and 11 versus 9% in
KT5, and 14 versus 14% in KT7). The KT1 subclones all
showed clearly reduced labeling of the mitochondrial transla-
tion products, with a relatively pronounced abnormal band
(asterisks) (barely visible for clone 4 because of the extreme
decrease in protein synthesis), and strongly decreased 02
consumption (Fig. 3). The KT5 subclones showed heterogene-
ity in the phenotypic expression of the mutation; two, sub-
clones 5 and 6, exhibited a variable reduction in labeling of the
mtDNA-encoded polypeptides, with a relatively large amount
of the abnormal band and a strong reduction in 02 consump-
tion, while the others showed a normal or near-normal level of
labeling, with a small or negligible amount of abnormal band
and a substantial to strong decrease in 02 consumption. The
K7 subclones, except for subclone 1, which exhibited a small
amount of the characteristic abnormal band recognizable for
its diffuse appearance (asterisk), showed a normal mitochon-
drial translation pattern, although with somewhat decreased
labeling of the protein products; furthermore, they exhibited a
variable reduction in 02 consumption (Fig. 3).
Complementation of defects caused by the MERRF muta-
tion by a small minority of wild-type mtDNA. The data
discussed in the two previous sections indicated that wild-type
mtDNA, even when present in relatively small amounts, can
exert a protective effect against manifestation of the MERRF
mutation-associated respiration defect. Figure 4a summarizes
the relationship between the proportion of wild-type mtDNA
and respiratory capacity in different MERRF transformants
isolated in the present work and tested at various times after
their isolation. The diagram clearly illustrates the existence of
a sharp transition, with a mid-point at a wild-type mtDNA
proportion of -8%, in the ability of wild-type mtDNA to
protect against manifestation of the respiration defect, with
full protection by -10% wild-type mtDNA (Fig. 4a). During
prolonged growth of the KT7 transformant, while the percent-
age of wild-type mtDNA decreased from -17 to -7.5%,
passing through the transition in its protective capacity men-
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FIG. 4. A small minority of wild-type mtDNA can prevent the
defective respiration (a and b) and protein synthesis (c) caused by the
MERRF mutation in different heteroplasmic transformants and their
subclones. (a and b) Relationship between proportion of wild-type
mtDNA and respiratory capacity in different heteroplasmic mitochon-
drial transformants (KT1, KT5, KT7, KT10, and KT11) at various
times after mitochondrion transfer (a) and in the KT1, KT5, and KT7
subclones (b). (c) Relationship between proportion of wild-type
mtDNA and amount of radioactivity in the abnormal protein band,
expressed relative to the total amount of label in the ND5, COI, and
ND4 translation products, in different KT1, KT5, and KT7 subclones.
Each symbol represents a different subclone. WT, wild type.
tioned above, no significant change was observed in the
mtDNA content per cell (data not shown). This indicates that
the threshold in wild-type mtDNA proportion above which this
DNA protects against the phenotypic effects of the mutation
reflects an equivalent sharp threshold in the absolute amount
of wild-type mtDNA. The data for the KT1, KT5, and KT7
subclones also show a similar protective effect of wild-type
mtDNA against the phenotypic expression of the MERRF
mutation, but the mid-point transition is displaced towards a
12% proportion of wild-type mtDNA for unknown reasons
(Fig. 4b).
In order to investigate whether the protective effect of
wild-type mtDNA involved an interaction of the wild-type and
mutant gene products, advantage was taken of the fact that the
abnormal band migrating slightly faster than ND4 which was
mentioned above (Fig. 2b and Fig. 3) provided a molecular
marker of the protein synthesis defect associated with the
MERRF mutation. Figure 4c shows the relationship between
the proportion of wild-type mtDNA and the amount of radio-
activity in the abnormal band, expressed relative to the total
amount of label in the ND5, COI, and ND4 translation prod-
ucts, in different KT1, KT5, and KT7 subclones. Again, there
appears to be a sharp transition, with a mid-point at a wild-type
mtDNA proportion of -9%, above which the abnormal band
decreases sharply in amount. This result indicates that the
threshold in the protective effect of wild-type mtDNA involves
primarily the restoration of normal mitochondrial protein syn-
thesis and, as a consequence, the re-establishment of respiratory
competence. Furthermore, and more importantly, the disap-
pearance of the abnormal band strongly suggests that the
protective effect depends in part on the intermixing and coop-
eration of the wild-type and mutant gene products.
Absence of complementation between two mtDNAs carrying
the MERRF and MELAS mutations independently introduced
into the same p0 cell. There are two possible mechanisms
underlying the genome interactions indicated by the results of
the experiments discussed in the previous section. First, it is
possible that the individual myoblast mitochondria introduced
into p0206 cells contained both wild-type and mutant genomes
as a result of the original mutation event and that this
intramitochondrial heteroplasmy was maintained in the trans-
formants. The second possibility is that fusion of the organelles
produced or enhanced the intermixing and interactions of the
two genomes. In order to test directly the capacity of mito-
chondrial genomes carried in originally distinct organelles to
interact with each other in the p0 transformants, advantage was
taken of the ability to independently introduce mitochondria
carrying mtDNA with the MERRF mutation in the tRNALYS
gene and mitochondria carrying mtDNA with the MELAS
mutation in the tRNALeU(UuR) gene into the same p0 cell. The
results presented in the previous section and earlier observa-
tions (8) strongly suggested that the two mutations are reces-
sive and therefore susceptible to complementation by the
products of wild-type genes if there are interactions between
the mutant and the wild-type genomes.
Two p0206 transformants, 59A and 2SD, derived from two
genetically unrelated MELAS patients (8), were fused with an
excess of cytoplasts from the p0701.2a transformant pT72,
derived from an MERRF patient (9), and 116 clones were
isolated from 12 96-microwell plates, as detailed in Materials
and Methods. Screening of the 116 clones for the MERRF
mutation led to the identification of 6 positive clones. The very
low yield of such clones substantively excluded the possibility
that they represented mixed clones. Figures 5a and b show the
analysis of the MERRF and MELAS mutations, carried out by
PCR amplification and NaeI and ApaI digestion, respectively,
in the parental lines (pT72, 59A, and 2SD), in the six two-step
cybrids (59A x pT72-1OA, 59A x pT72-1OB, 2SD x pT72-24,
59A X pT72-22, 59A x pT72-34, 2SD x pT72-25, and 2SD x
pT72-45), and in 143B cells. pT72 mtDNA exhibited only the
MERRF mutation, while the mtDNA from 59A and 25D cells
carried only the MELAS mutation. Five of the six two-step
cybrid clones, which were analyzed 42 to 99 days after fusion,
exhibited both the MELAS and the MERRF mutations in
various proportions. One clone (59A x pT72-10), which was
analyzed at two different times after fusion, 65 days (1OA) and
114 days (1OB), on the contrary, surprisingly showed only the
MERRF mutation at both times. Whether this clone arose
from fusion of an MERRF mutation-containing cytoplast with
a wild-type cell present in the MELAS transformant popula-
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FIG. 5. Genotype of p°206 cells transformed sequentially with MELAS mutation-containing and MERRF mutation-containing mitochondria.
(a and b) Detection of the MERRF and MELAS mutations in the parental cell lines, in 143B cells, and in the double-genome transformants
(analyzed 42 to 99 days after fusion). (a) The MERRF mutation was analyzed, as described in Materials and Methods, by running the PCR
products on a 5% polyacrylamide gel in the presence of the 1,075-bp XmnI-KpnI fragment of pBluescript KS+ DNA as an internal digestion
marker. The wild-type PCR product from the DNA of transformants 59A, 2SD, and pT72 exhibited the same size (174 bp) as the 143B-derived
PCR product. Lane KS+/Xmn I/Kpn I, a fragment produced by XmnI-KpnI cleavage of pBluescript KS+ DNA. (b) The MELAS mutation was
analyzed as described by Yoneda et al. (51). The expected sizes of the PCR product (330 bp) and of the fragments produced by ApaI digestion
of the MELAS mutation-containing PCR product (214 and 116 bp) are indicated. lin.KS+, KS+ DNA linearized with XmnI, added as an internal
marker for completion of digestion. Lane M, HaeIII-digested pBluescript KS+ DNA. (c) Percentages of MERRF mtDNA, MELAS mtDNA, and
wild-type (WT) mtDNA in the double-genome transformants and in the parental cell lines, estimated from densitometric analysis of the
electrophoretic patterns shown in panels a and b by using the standard curves shown in Fig. 1 and in Yoneda et al. (51). (d) Amounts of mtDNA
per cell in the double-genome transformants and in the parental cell lines.
tion or from a genotype shift of this double-genome transfor-
mant towards the MERRF genotype is not known.
Figure 5c shows the percentages of MERRF mtDNA,
MELAS mtDNA, and wild-type mtDNA observed in the above
transformants and in the parent cell lines. The MERRF
mtDNA content varied among the five double-genome trans-
formant clones between -64 and -87%, the MELAS mtDNA
content varied between -12 and -35%, and the wild-type
mtDNA content varied between 0 and -2%. Figure Sd shows
the relative mtDNA amount per cell in the transformants and
in the parental cell lines. The mtDNA content per cell in the
59A parental line and in the double-genome transformants was
fairly similar to the level in 143B cells. By contrast, the 2SD
and pT72 parental lines and the 59A x pT72-1OA and
59A x pT72-1OB transformants exhibited a large increase (245
to 325%) in mtDNA content relative to the 143B cells. This
increase presumably reflects a compensatory phenomenon
stimulated by the presence of functionally defective mitochon-
dria. The fact that this increase in mtDNA content did not
persist in the double-genome transformants derived from 2SD
and pT72 may indicate a change in nuclear gene content
and/or activity resulting from the fusion event.
~~~ ma
_~~~C -~ C CM CO CXJC
C 0. 0.0 0. C
CD cm XXxx Xx
X .Q 1fe a JC: D
i*.40-7--7-
.M.!- .
VOL. 14, 1994
2706 YONEDA ET AL.
a <: m
o o e
_m
x
a
4'mr r-N
-rL 0La,
b
ND5
CYTb j_-
ND2-- a
ND1-
coilI-~
A6/ -
ND6--
ND3---
ND4LV.
AB--
a
CN wt Ln LO
¢5l N ~CS
m
e >s ~~~XX <: <: a a(
LO
:l
FIG. 6. Mitochondrial protein synthesis of double-genome trans-
formants (analyzed 42 to 99 days after fusion) and of the parental cell
lines. Shown are the labeling patterns after a 2-h [35S]methionine pulse
(25 pLg of protein per sample). Symbols are defined in the legend to
Fig. 2b.
It was shown above that 10% or more of wild-type genes
have a fully protective effect against the manifestation of the
biochemical defects caused by the MERRF tRNALYS mutation,
as reported for the MELAS tRNALeu(UUR) mutation (8). In
the present experiments, the MERRF mutation-containing
mtDNA was expected to act like wild-type mtDNA in protect-
ing the cell against the MELAS mutation if intergenome
complementation occurred. Similarly, the MELAS mutation-
containing mtDNA was expected to act like wild-type mtDNA
in protecting against the MERRF mutation. The sum of
wild-type mtDNA and MERRF mutation-containing mtDNA
varied between 65 and 72% and the sum of wild-type mtDNA
and MELAS mutation-containing mtDNA varied between 29
and 36% in every double-genome transformant clone except
2SD x pT72-24. However, in this clone, the sum of wild-type
mtDNA and MELAS mutation-containing mtDNA was 14%,
i.e., above the threshold for protection against the phenotypic
effect of the MERRF mutation. Therefore, it was expected that
if there was genome interaction, there would be reciprocal
complementation between mtDNA containing the MERRF or
the MELAS mutation and mtDNA lacking that mutation in all
five double-genome transformants. On the contrary, it is clear
from Fig. 6 that the labeling of the mitochondrial translation
products in the double-genome transformants (measured 42 to
99 days after fusion) during a 2-h [35S]methionine pulse was
lower than the labeling in the parental cell lines. Particularly
striking is the marginal labeling of the mitochondrial transla-
tion products in the transformants 59A x pT72-22, 59A x
pT72-34, 2SD x pT72-25, and 2SD x pT72-45 (Fig. 6b). Densi-
tometric quantitation of the labeling of the mtDNA-encoded
polypeptides in the four double-genome transformants men-
tioned above showed a level of about 1% of the value observed
in 143B cells (Fig. 7a). In agreement with the protein labeling
data, there was no recovery of respiration capacity in any of the
double-genome transformants, their rates of 02 consumption
(measured within a few days from the protein synthesis anal-
ysis) varying between 6.8 and 14% of that in 143B cells (Fig.
7b). In particular, in the four transformants with a negligible
level of mitochondrial protein synthesis, the rate of 02 con-
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FIG. 7. Quantitation of mitochondrial protein synthesis (a) and
rate of °2 consumption (b) in the double-genome transformants and in
the parental cell lines. In panel a, the level of total mitochondrial
protein synthesis was estimated from densitometric analysis of the
electrophoretic patterns shown in Fig. 6a and b.
sumption (0.34 to 0.48 fmol/min/cell) approached the level
found in p°206 cells (25). An interesting observation is the
relatively high level of labeling of the mitochondrial translation
products(a60% of the level in 143B) and rateOfo2consump-
tion(p30% of the level in 143B) in the parental line 2SD,
which had the highest mtDNA content(o3.2 times that in
143B). A comparison of the data in Fig./c and d with those in
Fig. 7a and b shows that the lower labeling of the mitochon-
drial translation products and lower rateOf o2c0onmp in
the double-genome transformants compared with the parental
lines correlate to a good extent with a decrease in mtDNA
content.
Lack of complementation between exogenous CAP' mtDNA
and resident CAP' mtDNA in 143B cells. The apparent
absence of complementation between the MERRF and
MELAS mutations independently introduced into p0206 cells,
indicated by the experiments discussed in the previous section,
was at variance with previously reported findings (35). These
findings had been interpreted to suggest that HT1080 mtDNA,
carrying a 16S rRNA gene mutation that conferred CAP
resistance of mitochondrial protein synthesis on the cells,
allowed the synthesis of a HeLa cell mtDNA-encoded variant
ND3 polypeptide (originally named MV2 and subsequently
renamed ND3' on the basis of the functional identification of
the ND3 gene [9]) in the presence of CAP after introduction by
cybrid or hybrid fusion into HeLa cells. This interpretation
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implied an interaction of CAP' ribosomes from HT1080 cell
mitochondria with mRNA from HeLa cell mitochondria. The
presence of the variant ND3' polypeptide in HeLa cells has
been correlated with a mutation in the ND3 gene that converts
an asparagine codon to an aspartic acid codon, and its faster
electrophoretic mobility compared with that of the normal
ND3 polypeptide has been interpreted to result from either
proteolytic digestion, the loss of a potential glycosylation site,
or the addition of a charge group (34). In order to verify the
occurrence of interactions between the products of CAPY and
CAPS mtDNAs carried in originally distinct organelles in the
same 143B nuclear background of the double-genome trans-
formants investigated here, cybrids were constructed between
cytoplasts from CAP23, a derivative of the human cell line
VA2B, which carries an mtDNA mutation in the 16S rRNA
gene conferring CAP resistance (26, 31), and the CAPS 143B
cell line. A favorable situation in these experiments was the
fact that CAP23 exhibits the same ND3 polymorphism de-
scribed for HeLa cells and that 143B cells synthesize the
normal ND3 gene product.
Two fusion experiments were carried out between cytoplasts
from CAP23 cells and a large excess of 143B cells. Figures 8a
and b show the analysis of the CAP' mutation by PCR
amplification and AatII digestion in the parental cell lines
143B, VA2B (the parent of CAP23), and CAP23 and in the
cybrids obtained by fusion of CAP23 cytoplasts and 143B cells
in the first and second fusion experiments. The 143B and
VA2B cells exhibited 100% wild-type mtDNA, while CAP23
cells exhibited nearly homoplasmic (89%) mutant mtDNA. All
13 cybrids isolated in the first experiment, which had been
maintained for 57 or 58 days in the presence of 100 ,ug of CAP
per ml, exhibited nearly homoplasmic (83 to 91%; average,
89%) mutant mtDNA (Fig. 8a). By contrast, the 16 cybrids
isolated in the second experiment, which had been kept in
medium containing 100 ,ug of CAP per ml for 36 days or
maintained in this medium for 31 days and then transferred to
a medium containing 25 jig of CAP or 25 ,ug of CAP plus 50
jig of uridine per ml for 5 days, exhibited lower proportions of
CAPr mtDNA, from 9 to 53% (average, 27%). Figure 8b shows
the genotype analysis of the parental cell lines 143B, VA2B,
and CAP23 and of eight cybrids with various proportions
(between 10 and 89%) of CAP' mtDNA, chosen from those
isolated in the first and second fusion experiments.
Figure 8c shows the pattern of mitochondrial protein syn-
thesis after a 2-h exposure of the cells to [35S]methionine in the
absence and presence of 100 jig of CAP per ml in the parental
lines and in six of the eight cybrid clones. The mitochondrial
translation patterns observed in the absence of CAP in 143B
cells on one side and in VA2B and CAP23 cells on the other
were identical except for the exclusive presence of the ND3
normal gene product in 143B cells and for a greatly reduced
amount of the ND3 polypeptide and a predominant amount of
the variant ND3' product in VA2B and CAP23 cells. The
coexistence of a small amount of the ND3' variant polypeptide
with a prevalent normal ND3 product had been reported
previously for HeLa cells (35). Also to be noticed is the fact
that the labeling of the mitochondrial translation products in
CAP23 cells was significantly reduced compared with that in
either 143B cells (by 25%) or VA2B cells (by 39%), in
agreement with earlier observations (50). Protein synthesis was
nearly completely sensitive (97 to 98%) to 100 jig of CAP per
ml in 143B and VA2B cells and 85% resistant to the drug in
CAP23 cells.
Two cybrids (5 and 16) with strongly predominant (89 and
85%, respectively) CAPr mtDNA exhibited nearly complete
resistance of their protein synthesis to CAP. By contrast,
mitochondrial translation was nearly completely sensitive to
CAP in two cybrids (36 and 43) with minor proportions of
CAPr mtDNA (12 and 10%, respectively). Two cybrids (35 and
39) with intermediate proportions (59 and 61%, respectively)
of CAPr mtDNA exhibited intermediate levels of resistance of
their protein synthesis to CAP. After correction of the protein
synthesis data for the double-genome transformants for the
difference in protein labeling between CAP23 cells in the
presence of CAP and VA2B cells in the absence of CAP, there
is a reasonably good proportionality between the percentage of
protein synthesis that is resistant to CAP and the percentage of
CAP' mtDNA (Fig. 8d, solid circles and solid line), in agree-
ment with the assumption of genetic independence of the
CAP23-derived and 143B-derived mitochondria. If no correc-
tion is applied to the protein synthesis data, the line best fitting
the data (dashed line in Fig. 8d) becomes more pronouncedly
curved, as would be expected if there were at least partial
interactions between the CAPr and CAPS genomes, with the
latter being dominant. However, a dominance of the CAPS
allele would be in contrast to the available evidence from
bacterial systems indicating that the CAPS ribosomes are not
"frozen" by CAP on the polysomes and are therefore not
expected to block the passage of the resistant ones (18); also,
the well-documented isolation of CAPr mutants of Saccharo-
myces cerevisiae (4, 7) and mammalian cells (44, 48) under
selective conditions, which would require the initial expression
of single mutant mtDNA molecules mixed with wild-type
molecules, argues strongly against a dominance of the CAPS
allele. Therefore, the data are most consistent with the con-
clusion that the CAPr and CAPS genomes in these cybrids are
phenotypically independent.
Additional evidence in favor of the above conclusion was
provided by analysis of the expression, in the absence and
presence of CAP, of the normal ND3 gene product and ND3'
variant product in the cybrids (Fig. 8c). In fact, the two cybrids
with strongly predominant CAPr mtDNA (5 and 16) exhibited
a prominent ND3' band and a weak ND3 band in both the
absence and the presence of CAP. It seems very likely that this
weak ND3 band derives from the mitochondria containing
wild-type mtDNA in heteroplasmic form transferred with the
CAP23 cytoplasts. Conversely, the two cybrids with minor
proportions of CAPr mtDNA (36 and 43) exhibited a promi-
nent ND3 band in the absence of CAP and only a trace of this
band in the presence of CAP; a very weak ND3' band was
visible in these two cybrids in both the absence and the
presence of the drug. In the two cybrids with intermediate
proportions of CAPr mtDNA (35 and 39), the protein labeling
pattern in the absence of CAP showed a fairly strong ND3
band which was markedly reduced (-88%) in the presence of
CAP and a weaker ND3' band which was only slightly affected
(-20%) by exposure of the cells to the drug. This result was
consistent with the phenotypic independence of the CAP' and
CAPS genomes in the cybrids. The fact that the labeling of the
ND3' band in the latter experiments (ND3'/[ND3 + ND3'] _
15%) was lower than expected from the proportion of CAPr
mtDNA (59 to 61%) is presumably due at least in part to the
lower protein-synthetic capacity of the CAP23 mitochondria.
DISCUSSION
The present article has addressed fundamental questions of
mammalian mitochondrial genetics, namely, whether mutant
and wild-type mtDNA molecules can interact with each other
within a cell and whether the distribution of the two types of
mtDNA molecules among mitochondria can influence this
capacity. Two different situations were investigated, one in-
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volving the simultaneous introduction into a p°206 cell of
mitochondria containing mtDNA with a deleterious mutation
and the corresponding wild-type mtDNA from the same donor
cell, and the other involving the introduction of mitochondria
carrying a mutant or wild-type gene into cells already contain-
ing the corresponding wild-type or mutant allele. In both
situations, transformants exhibiting various ratios of the two
types of mtDNA were analyzed.
The first situation was investigated by introducing into p0206
cells mitochondria from cells of a patient carrying in hetero-
plasmic form the mitochondrial tRNALYS mutation associated
with the MERRF encephalomyopathy. In these experiments,
the occurrence of interactions between the products of mutant
and wild-type mtDNAs was strongly suggested by the disap-
pearance of the abnormal protein band migrating slightly
faster than ND4 (5, 9), which is produced as a result of the
mutation. Previous observations (9) on p0 cell transformants
carrying the MERRF A-->G transition in the tRNALYS gene
had indicated a direct relationship between the lysine residue
content of the various mitochondrial translation products and
the severity of inhibition of their synthesis, pointing to an
alteration of tRNA function as being responsible for the strong
depression of mitochondrial protein synthesis caused by the
mutation. Although the origin of the abnormal band migrating
faster than ND4 has not been identified yet, it is very likely that
it represents a premature termination product of the transla-
tion of the mRNA for one of the three largest mitochondrial
genes, i.e., ND5, COI, and ND4. Recent evidence (14a) has
indicated that there is a strong decrease (60 to 70%) in the
charging capacity for lysine of the mutated tRNALYS. In the
present work, the almost complete disappearance of the
abnormal band in the heteroplasmic transformants containing
more than 10% wild-type mtDNA has clearly shown that there
was extensive intermixing of wild-type and mutant gene prod-
ucts in these transformants and that the MERRF mutation
behaved as a recessive, a finding which is consistent with a
tRNALYS dysfunction caused by the mutation. Furthermore,
these results have strongly suggested that the protective effect
by a small minority of wild-type mtDNA depends, in part at
least, on the interaction between the mutant and wild-type
gene products.
A strikingly different conclusion from that discussed above
concerning mitochondrial genome interactions has emerged
from experiments involving the introduction of mitochondria
containing a mutant or wild-type gene into cells already
carrying the corresponding wild-type or mutant allele. Two
such types of experiments were carried out. The first type of
experiments took advantage of the availability of two mtDNAs
carrying nonallelic disease-causing mutations, each causing a
recognizable defective phenotype in the cells carrying it; this
allowed a test of the occurrence of complementation between
mitochondrial genomes carried by originally distinct or-
ganelles, with no significant background being associated with
absence of complementation. These experiments involved the
introduction into p0 cell transformants nearly homoplasmic for
the MELAS mutation of mitochondria carrying about 100%
mtDNA with the MERRF mutation. In these experiments, no
evidence of cooperation between the products of the two
mtDNAs was observed even 3 months after introduction of the
second mutation, as judged from the absence of recovery of
respiratory competence and of a normal rate of mitochondrial
protein synthesis.
The recessive nature of the MERRF mutation and the
observation that as little as 10% wild-type genes is able to fully
complement the biochemical defects caused by the mutation
would tend to exclude the possibility that this lack of cooper-
ation between the MERRF and the MELAS genomes re-
flected an interference by the excess of mutant tRNALYS
expected in the double-genome transformants analyzed here
with the function of the wild-type tRNALYS. One can likewise
exclude the possibility that the majority of the MERRF
mutation-carrying genome is "incompatible" with the p0206
nuclear background of the recipient MELAS transformants. In
fact, it has been shown previously that the mitochondrial
genome of the same haplotype as that investigated here but
lacking the MERRF mutation can confer full respiratory
competence and a normal level and pattern of mitochondrial
protein synthesis on p0206 cells (9). In the case of the MELAS
mutation, the previously reported full protection from the
phenotypic effects of the mutation exerted by 10% wild-type
mtDNA (8) also suggests that the mutation is recessive, arguing
against significant interference by the mutated tRNAL-UeuUR)
with the wild-type tRNALu(UUR). Even if the MELAS muta-
tion were dominant, it seems extremely unlikely that a minority
of MELAS mutation-carrying genomes would have a more
drastic effect on mitochondrial protein synthesis and respira-
tion than was previously observed in p0 cell transformants
carrying nearly 100% of the same MELAS mutant genomes
(8).
The possibility that two unlinked recessive mutations occur-
ring in the same cells may give a dominant phenotype, as has
been described for some nuclear systems, also has to be
considered. If this is the situation here, it may have produced
a result similar to what would be expected from lack of
complementation. However, the clear cases of such a phenom-
enon described previously are those in which the two muta-
tions occur in proteins that interact with each other, like the
subunits of an oligomeric complex. In another case, recently
reported, concerning the effect of haywire gene mutations in
testis-specific tubulin mutants of Drosophila melanogaster (33,
38), one mutation alters a protein (haywire) that affects the
expression of another gene product (,B-tubulin) required at
high levels, and the other mutation alters the latter gene
product. It seems very unlikely that the structural or functional
gene product interactions occurring in the two situations
mentioned above would apply to the case of two distinct tRNA
gene mutations, considering the protective effect of only 10%
wild-type genes against the phenotypic manifestation of either
mutation.
On the basis of the evidence discussed above, the most
plausible interpretation of the phenotype of the double-ge-
nome transformants of p0206 cells is that the products of the
cells, and six of the cybrids analyzed in panel b. (d) Relationship between CAP resistance of mitochondrial protein synthesis, estimated from
densitometric analysis of the electrophoretic patterns shown in panel c (not shown for cybrids 21 and 24), and proportion of mutant mtDNA in
the six cybrids with various levels of CAPr mutation analyzed in panel c and in two additional cybrid clones (21 and 24) with intermediate levels
of CAP' mtDNA (57 and 58%, respectively) (panel b). Solid circles represent the protein synthesis data for the cybrids after correction for the
difference in protein labeling between CAP23 cells in the presence of CAP and VA2B cells in the absence of CAP, and the solid line represents
the curve best fitting the data. The CAP23 value has been similarly corrected. The dashed line represents the curve best fitting the uncorrected
protein synthesis data. (a and b) IDM, internal digestion marker (see Materials and Methods). (b) Lane M, HaeIII-digested pBluescript KS+
DNA.
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MERRF mutation- and the MELAS mutation-carrying
mtDNAs, originally carried in distinct organelles, did not
interact with each other to any appreciable extent in the
cybrids investigated here. This lack of genome interaction did
not reflect the particular behavior of the MELAS and MERRF
mutations but rather a more general phenomenon. In fact,
similar results were obtained in a second type of experiment
involving the introduction of mitochondria from CAP23 cells,
carrying a nearly homoplasmic CAPr mutation in their
mtDNA, into CAPS 143B cells. In these experiments also, no
evidence of genome interaction was observed in the cybrids
between the CAPr and CAPS mtDNAs, as judged from the
reasonably good proportionality between percentage of resid-
ual mitochondrial protein synthesis in the presence of CAP
and percentage of CAP' genomes and from the lack of
synthesis, in the presence of the drug, of the 143B mtDNA-
encoded normal ND3 polypeptide.
The reason for the different conclusion reached by others in
similar earlier experiments with cybrids or hybrids between
CAPr HT1080 and CAPS HeLa cells (35) is not clear. Although
one cannot exclude a role for the different nuclear background
in the cybrids analyzed in the present and in the previous work
(143B in the present CAPr_CAPS cybrids and HT1080 in the
earlier-investigated CAPr_CAPS cybrids), it should be re-
marked that, in the above-cited work, the high sensitivity to
CAP (70 to 90%) of both the gene products linked to the CAPS
mtDNA and of those linked to CAPr mtDNA, including the
putative ND3 and ND3' bands, makes those results difficult to
interpret. In the present work, additional evidence against any
significant cooperation between CAPS and CAPr mtDNA was
provided by the nearly complete replacement of the resident
CAPS mtDNA by the exogenous CAPr mtDNA observed in the
cybrids 8 weeks after fusion. In fact, if there was such a
cooperation, one would expect significant proportions of CAPS
mtDNA to persist in the cybrids because of the lack of selective
pressure against the CAPS mtDNA. These results confirm
those obtained in earlier experiments, in which single or-
ganelles from CAP23 cells were injected into cells from two
genetically independent human CAPS cell lines. In fact, in
these experiments, a rapid complete replacement of the resi-
dent CAPS mtDNA by the CAPr mtDNA was demonstrated
(26).
The fundamental conclusion of the experiments discussed in
this article is that interactions of mitochondrial genomes
originally carried in distinct organelles occur rarely, if at all, in
the cell lines analyzed here. Although the present work has not
addressed directly the question of whether fusion occurred
between organelles carrying different mtDNAs, the most plau-
sible hypothesis is that the lack of interaction between the two
genomes reflected their physical segregation in separate or-
ganelles, i.e., absence of mitochondrial fusion. There is other
evidence in the literature that supports the idea that two types
of mtDNA originally located in separate organelles tend to
remain segregated in mammalian cells, including the gradual
elimination of HeLa cell mtDNA in hybrids of HeLa cells and
fibroblasts (21, 49) and the complete switch, in only one or a
few generations, of mtDNA genotypes in Holstein cows (2, 28,
36). A model assuming that the unit of segregation of mam-
malian mtDNA is the organelle itself and that the rapidity of
segregation of mitochondrial alleles within heteroplasmic oo-
cytes is therefore influenced by whether the individual or-
ganelles themselves are homoplasmic or heteroplasmic (23)
likewise argues in favor of the genetic independence of the
individual mitochondria within a mammalian cell.
The cell mosaicism observed in the distribution of mutant
mtDNA in several mtDNA-encoded diseases (5, 9, 30, 41)
supports the same concept. The observation of heterogeneity
in membrane potential among mitochondria in the same cell is
also consistent with autonomy of the organelles (42). In
conjugated paramecia also, no complementation has been
observed between genetically different types of mitochondria
(1). On the other hand, the evidence of mtDNA complemen-
tation and recombination clearly indicates that mitochondrial
fusion does occur in other organisms, such as S. cerevisiae (10),
Chlamydomonas spp. (6), and plants (39, 46). However, it has
also been found in yeast cells that, in p+ x p+ crosses, mtDNA
mixing is not extensive and appears to be limited to that
portion of the zygote which gives rise to medial buds and,
furthermore, that the sorting of mtDNA is controlled differ-
ently from that of the bulk matrix protein constituents (3). In
mammalian cells, the apparent lack of recombination between
mtDNA molecules (11) certainly reduces the need for mito-
chondrial fusion. However, in mammalian systems, the evi-
dence for the existence of an interconnecting mitochondrial
network in some cell types in vivo also suggests the possibility
that mitochondrial fusion may occur in certain situations under
physiological or developmental control.
The observation of restoration of normal mitochondrial
protein synthesis in p0 cell transformants derived from hetero-
plasmic cells from an MERRF patient and containing more
than 10% wild-type mtDNA and the previously reported
findings of fusion proteins (20) and of competition for tRNAs
(41) in cybrids and skeletal muscle segments carrying large
mtDNA deletions have to be interpreted in the light of the
evidence obtained in the present work on the lack of interac-
tions between the products of two mtDNAs carried by origi-
nally distinct organelles. In fact, it seems likely that, in all the
above-mentioned cases, in which there was obviously interac-
tion of the mutant and wild-type genomes, these coexisted in
the same organelles from the time of the mutation. Since each
mitochondrion in most mammalian cells contains several
mtDNA molecules, every mutant mtDNA molecule will in the
beginning coexist in the same organelle with wild-type mole-
cules. It is very reasonable to think that cells in which this
intramitochondrial heteroplasmy is maintained will have a
selective advantage because of the possibility of complemen-
tation that this situation allows. Therefore, the different results
obtained in the two situations analyzed in the present work,
namely, the occurrence of interactions of mutant and wild-type
mitochondrial DNAs originally coexisting in the same cell and
the failure of interaction when the two DNAs are introduced
into a cell within distinct organelles, may well reflect the
different complementation behavior of the two DNAs in the
case of intramitochondrial versus intermitochondrial hetero-
plasmy. If this interpretation is correct, it would imply a
fundamental role for mtDNA sorting among different or-
ganelles in determining the oxidative phosphorylation pheno-
type in mammalian cells.
It seems indeed a very plausible idea that mitochondrial
organization, which is under nuclear control and varies among
different cell types, may be an important parameter affecting
mitochondrial gene expression in these cells. The present
observations have significant implications for the possible role
of genetic independence of individual mitochondria in the
transmission of mtDNA-encoded diseases and for potential
therapeutic approaches involving mtDNA- or mitochondrion-
mediated gene transfer.
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